NCT01279538已完成1 期
A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 21
- 主要终点
- Pharmacokinetic assessment through analysis of blood samples
研究概览
简要总结
The purpose of the study is to assess the Pharmacokinetics (PK),
pharmacodynamics (PD), safety and tolerability of ASKP1240 when administered to subjects who received a de novo kidney transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is a recipient of a de novo kidney transplant from a living or deceased donor
- •Prior to randomization, the subject has a post-transplant serum creatinine value that is at least 30% decreased from the pre-transplant value and requires no dialysis
- •Female subject of child bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment or upon hospitalization and must agree to maintain effective birth control during the study
- •All sexually active male subjects must agree to use an adequate method of contraception throughout the study period and for 90 days after the last dose of study drug and agrees to no sperm donation until the end of the study, or for 90 days after the last dose of study drug, whichever is longer
- •Subject must be willing and able to comply with the study requirements including prohibited concomitant medication restrictions
排除标准
- •Prior to randomization, subject will receive antibody induction therapy (e.g., thymoglobulin, basiliximab, daclizumab, OKT3, alemtuzumab)
- •Subject has previously received or is receiving an organ transplant other than a kidney
- •Recipient has a positive T or B cell crossmatch
- •Subject has ABO blood type incompatibility with their donor
- •Subject has received intravenous immunoglobulin (IVIG) therapy in the 3 months prior to first dose of study drug
- •Recipient or donor is known by medical history to be seropositive for human immunodeficiency virus (HIV)
- •Subject had a thromboembolic event (e.g., myocardial infarction, cerebrovascular event, pulmonary embolus, deep vein thrombosis, peripheral arterial thromboembolic event) in the past 5 years or if the subject is on specific therapy for prophylaxis or treatment of such an event. Low dose aspirin (81 mg) therapy is not considered exclusionary. NOTE: A one-time event of arterio-venous (AV) fistula dialysis access thrombosis is not exclusionary. Subjects with recurrent AV fistula thrombosis or those on systemic medications to prevent reoccurrence are excluded
- •Subject has a current malignancy or a history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
- •Subject has an uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives
- •Subject is concurrently participating in another drug study or has received an investigational drug up to 8 weeks (depending on medication) prior to transplant
- •Subject has previously received ASKP1240 or participated in a study involving ASKP1240
- •Subject has abnormal chest x-ray indicative of acute or chronic lung disease on a prior examination within 3 months prior to randomization
- •Subject has abnormal electrocardiogram (ECG) considered as clinically significant on a prior examination within 3 months prior to randomization
- •Subject has uncontrolled intercurrent illness, including, but not limited to ongoing or active infection, any clinically significant cardiac disease, seizure disorder, or psychiatric illness/social situations that would limit compliance with study requirements
- •Subject has received live or live attenuated virus vaccinations within the last 30 days prior to first dose of study drug
- •Subject has a clinical condition which would not allow safe conduct and completion of the study
- •Subject is pregnant or lactating
研究组 & 干预措施
ASKP1240 lowest dose
Experimental
Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
干预措施: bleselumab (Drug)
ASKP1240 low dose
Experimental
Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
干预措施: bleselumab (Drug)
ASKP1240 high dose
Experimental
Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
干预措施: bleselumab (Drug)
ASKP1240 highest dose
Experimental
Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
干预措施: bleselumab (Drug)
Placebo
Placebo Comparator
Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
干预措施: Placebo (Drug)
结局指标
主要结局
Pharmacokinetic assessment through analysis of blood samples
时间窗: Up to Day 90
次要结局
未报告次要终点
研究者
研究点 (21)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101Acute AgitationNCT03624322Impel Pharmaceuticals38
已完成
1 期
Safety and Pharmacokinetic Study of C13-URA in Healthy VolunteersGastroparesisNCT01074710Otsuka Pharmaceutical Co., Ltd.8
已完成
1 期
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia PatientsGout and Asymptomatic HyperuricemiaNCT02317861AstraZeneca110
已完成
1 期
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)Ulcerative ColitisNCT04924114Merck Sharp & Dohme LLC57
已完成
2 期
Peginesatide for Anemia in Chronic Hemodialysis PatientsChronic Kidney DiseaseAnemiaChronic Renal FailureNCT00228449Affymax165